Rapport Therapeutics, INC Form 4 insider transactions

Jeffrey Sevigny, Chief Medical Officer of Rapport Therapeutics, reports the acquisition of stock options for 300,000 shares on April 1, 2025.

David Bredt, Chief Scientific Officer of Rapport Therapeutics, sold 8,500 shares of common stock at an average price of $10.8477 under a pre-arranged Rule 10b5-1 trading plan.

Troy Ignelzi, CFO of Rapport Therapeutics, discloses the purchase of common stock in the company.

Director Wendy Young purchased 6,000 shares of Rapport Therapeutics at an average price of $10.2083 on March 12, 2025.

Cheryl Gault, Chief Operating Officer of Rapport Therapeutics, reports the acquisition of 13,987 shares of common stock on March 3, 2025, according to a Form 4 filing.

Troy A. Ignelzi, CFO of Rapport Therapeutics, acquired 142,000 stock options on February 3, 2025, according to a Form 4 filing with the SEC.

Krishnaswamy Yeleswaram, Chief Development Officer of Rapport Therapeutics, was granted stock options for 110,000 shares on February 3, 2025.

David Bredt, Chief Scientific Officer of Rapport Therapeutics, acquired 100,000 stock options on February 3, 2025, according to a Form 4 filing.

CEO of Rapport Therapeutics, Abraham Ceesay, reports acquisition of 428,000 stock options.

Cheryl Gault, Chief Operating Officer of Rapport Therapeutics, was granted stock options for 129,000 shares on February 3, 2025.

Director Wendy B. Young acquired 29,756 stock options in Rapport Therapeutics on November 7, 2024.

Robert J. Perez, a director of Rapport Therapeutics, acquired stock options for 29,756 shares of common stock on November 7, 2024.

Director Paul M. Silva of Rapport Therapeutics acquired stock options for 29,756 shares on November 7, 2024.

Director Ramiro Sanchez acquired stock options in Rapport Therapeutics, Inc. on November 7, 2024.

James Healy, a director of Rapport Therapeutics, reports the acquisition of common stock through indirect holdings via several investment partnerships.

ARCH Venture Partners XII, LLC reports the conversion of Series A and Series B Preferred Stock to Common Stock in Rapport Therapeutics, Inc. upon the closing of the company's initial public offering.

Bradley S. Galer, Chief Medical Officer of Rapport Therapeutics, acquired stock options for 123,818 shares of common stock on June 6, 2024.

Cheryl Gault, Chief Operations Officer of Rapport Therapeutics, acquired stock options for 88,442 shares of common stock on June 6, 2024.

David Bredt, Chief Scientific Officer of Rapport Therapeutics, acquired stock options for 28,302 shares of common stock on June 6, 2024, at an exercise price of $17.

Krishnaswamy Yeleswaram, Chief Development Officer of Rapport Therapeutics, was granted stock options for 84,904 shares of common stock on June 6, 2024.

Third Rock Ventures converted its holdings of Series A and Series B Preferred Stock into Common Stock of Rapport Therapeutics upon the closing of the company's initial public offering.

Rapport Therapeutics CEO Abraham Ceesay was granted stock options to purchase 530,647 shares of common stock on June 6, 2024.

Director James Healy reports changes in beneficial ownership of Rapport Therapeutics common stock following the company's initial public offering.

Troy A. Ignelzi, CFO of Rapport Therapeutics, acquired stock options for 81,366 shares on June 6, 2024, according to a Form 4 filing.